콘텐츠로 건너뛰기
Merck
  • Anti-polymorphonuclear neutrophil antibodies in patients with leukopenia or neutropenia.

Anti-polymorphonuclear neutrophil antibodies in patients with leukopenia or neutropenia.

International journal of laboratory hematology (2009-07-15)
N E Riera, M Rosso Saltó, V Galán, K Canalejo, M Khoury, M Aixalá, G L Kantor, M Vermeulen, R Bengió, M M E De Bracco
초록

Immune humoral neutropenia (Np) could be the consequence of anti-polymorphonuclear neutrophil (PMN) antibodies, circulating immune complexes (CIC) and/or antibodies against myeloid precursors. Granulocyte immunofluorescence test (GIFT) and a leukoagglutination technique (LAGT) assays are recommended for its diagnosis. Fifty adult patients with secondary Np were screened for anti-PMN. GIFT by flow cytometry from viable PMN and LAGT were employed. In addition, CIC levels, low expression of CD16(b) (CD16 (b)(low)), PMN phenotype and sera tumor necrosis factor-alpha (TNF-alpha) were also evaluated. Direct IgG-PMN binding (dir-GIFT) was positive in 16% of the patients. Antibodies against autologous PMN were detected in 32% of the samples by indirect (ind)-GIFT and demonstrated in 70% of the sera by both ind-GIFT and/or LAGT. Predominance of human neutrophil alloantigen (HNA)-1b and HNA-2 expression was confirmed. CD16(b)(low) was detected in 16% of the patient's PMN and TNF-alpha in 68% of sera patients. Our results suggest that diagnosis of immune Np in the laboratory may be improved by focusing on patient's PMN together with the assessment of cellular markers.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Globulins Cohn fraction II, III human, lyophilized powder
Sigma-Aldrich
Globulins Cohn fraction IV-4 human